Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Nucleophosmin-1 mutations (NPM1(+)) occur in ∼30% of acute myeloid leukemia (AML) patients. Although typically associated with favorable prognosis, the beneficial impact of NPM1(+) decreases with increasing age in patients treated with standard intensive chemotherapy (IC) or hypomethylating agents (...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood Adv
Main Authors: Lachowiez, Curtis A., Loghavi, Sanam, Kadia, Tapan M., Daver, Naval, Borthakur, Gautam, Pemmaraju, Naveen, Naqvi, Kiran, Alvarado, Yesid, Yilmaz, Musa, Short, Nicholas, Ohanian, Maro, Pierce, Sherry R., Patel, Keyur P., Qiao, Wei, Ning, Jing, Sasaki, Koji, Takahashi, Koichi, Jabbour, Elias, Andreeff, Michael, Ravandi, Farhad, Kantarjian, Hagop M., Konopleva, Marina, DiNardo, Courtney D.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2020
נושאים:
Myeloid Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160266/
https://ncbi.nlm.nih.gov/pubmed/32251497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001267
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים